Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 100 mg - tablet, modified release - excipient ingredients: hyetellose; cetostearyl alcohol; magnesium stearate; purified talc; titanium dioxide; indigo carmine aluminium lake; hypromellose; iron oxide yellow; iron oxide black; macrogol 400 - ms contin is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms contin is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms contin is not indicated as an as-needed (prn) analgesia.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 60 mg - tablet, modified release - excipient ingredients: lactose; hyetellose; cetostearyl alcohol; magnesium stearate; purified talc; titanium dioxide; hypromellose; sunset yellow fcf; quinoline yellow; erythrosine; macrogol 400 - ms contin is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms contin is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms contin is not indicated as an as-needed (prn) analgesia.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 30 mg - tablet, modified release - excipient ingredients: lactose; hyetellose; cetostearyl alcohol; magnesium stearate; purified talc; titanium dioxide; indigo carmine; hypromellose; sunset yellow fcf; erythrosine; macrogol 400 - ms contin is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms contin is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms contin is not indicated as an as-needed (prn) analgesia.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

medsurge pharma limited - morphine sulfate pentahydrate 10 mg/ml;   - solution for injection - 10 mg/ml - active: morphine sulfate pentahydrate 10 mg/ml   excipient: hydrochloric acid nitrogen sodium chloride water for injection - the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

medsurge pharma limited - morphine sulfate pentahydrate 2 mg/ml;   - solution for injection - 2 mg/ml - active: morphine sulfate pentahydrate 2 mg/ml   excipient: hydrochloric acid nitrogen sodium chloride water for injection - the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

medsurge pharma limited - morphine sulfate pentahydrate 30 mg/ml;   - solution for injection - 30 mg/ml - active: morphine sulfate pentahydrate 30 mg/ml   excipient: hydrochloric acid nitrogen sodium chloride water for injection - the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

medsurge pharma limited - morphine sulfate pentahydrate 5 mg/ml;   - solution for injection - 5 mg/ml - active: morphine sulfate pentahydrate 5 mg/ml   excipient: hydrochloric acid nitrogen sodium chloride water for injection - the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Καναδάς - Αγγλικά - Health Canada

pharmascience inc - morphine sulfate - tablet (extended-release) - 15mg - morphine sulfate 15mg - opiate agonists

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

stat rx usa llc - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 15 mg - morphine sulfate extended-release tablets are an extended-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. morphine sulfate extended-release tablets are not intended for use as a prn analgesic. the morphine sulfate extended-release tablets 100 mg and 200 mg strengths are high dose, extended-release, oral morphine formulations indicated for the relief of pain in opioid-tolerant patients only. morphine sulfate extended-release tablets are not indicated for pain in the immediate postoperative period (the first 12 to 24 hours following surgery) for patients not previously taking the drug, because its safety in this setting has not been established. morphine sulfate extended-release tablets are not indicated for pain in the postoperative period if the pain is mild, or not expected to persist for an extended period of time. morphine sulfate extended-release tablets are o